IFM Investors’s Nektar Therapeutics NKTR Stock Holding History

IFM Investors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-990	Closed	-$270K	–	619
2019 Q3	$270K	Buy	990 +315	+47%	+$116K	0.01%	603
2019 Q2	$360K	Hold	675	–	–	0.02%	570
2019 Q1	$340K	Hold	675	–	–	0.02%	555
2018 Q4	$333K	Buy	675 +65	+11%	+$39.2K	0.03%	531
2018 Q3	$557K	Buy	610 +133	+28%	+$114K	0.04%	453
2018 Q2	$350K	Buy	+477	New	+$550K	0.03%	507

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

IFM Investors's NKTR Position: Q4 2019 in Review

IFM Investors sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 990 shares — an estimated $270K sold.

IFM Investors first reported a position in NKTR in Q2 2018 and held it in 6 quarters. The position peaked at $557K in Q3 2018. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

IFM Investors reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
IFM Investors sold 990 Nektar Therapeutics shares in Q4 2019, an estimated $270K.
IFM Investors first reported a position in Nektar Therapeutics in Q2 2018 and held it in 6 quarters.
IFM Investors's Nektar Therapeutics position peaked at $557K in Q3 2018.
281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on IFM Investors's 13F filing for Q4 2019, filed 13 Jan 2020.